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Abstract
Background: The epidermal growth factor receptor (EGFR) is an available target of effective anti-EGFR therapy for
human breast cancer. The aim of this study was to assess the presence of EGFR gene amplification and mutations
in breast cancer and to analyze the association between the statuses of these two gene alterations.
Materials and methods: EGFR gene amplification and mutations were investigated in formalin-fixed, paraffin-
embedded tissues from 139 Chinese female patients with breast cancer by means of fluorescence in-situ
hybridization (FISH) and fluorescently labeled real-time quantitative polymerase chain reaction (RT-PCR),
respectively.
Results: EGFR gene amplification was observed in 46/139 (33.1%) of cases by FISH. Based on RT-PCR, 2/139 (1.4%)
samples had EGFR gene mutations. Overall, only 1 (0.7%) of the cases was identified with both whole gene
amplification and mutation, and 92 (66.2%) of cases were negative for both. High gene copy numbers of EGFR had
significant correlation with the occurrence of EGFR protein expressions (P = 0.002).
Conclusion: In this study, EGFR mutations were presented in only two samples, indicating that EGFR mutations
should not be employed in future trials with anti-EGFR therapies for breast cancer. However, EGFR whole gene
amplification is frequently observed in patients with breast cancer. It will be of significant interest to investigate
whether EGFR gene copy number is a suitable screening test for EGFR-targeted therapy for breast cancer.
Keywords: breast cancer, epidermal growth factor receptor, EGFR, FISH, gene amplification, gene mutation, real-
time PCR.
Introduction
The human epidermal growth factor receptor (HER/
EGFR/ErbB) family of receptor tyrosine kinases is com-
prised of four transmembrane growth factor receptor
proteins that share similarities in structure and function.
The epidermal growth factor receptor (HER-1/EGFR/
ErbB1), encoded by the gene located on the short arm
of chromosome 7, is a member of this family of Type I
transmembrane tyrosine kinase receptors. EGFR is a 170
kDa transmembrane protein consisting of an intracellu-
lar domain (tyrosine kinase domain), a short
transmembrane and juxtamembrane domain, and an
extracellular domain (ligand-binding domain) with
ligand-activated tyrosine kinase activity [1]. EGFR can
be activated by various growth factor ligands, including
epidermal growth factor (EGF) and the transforming
growth factor-alpha (TGF-a). Ligand binding to EGFR
results in homo- or hetero-dimerization of EGFR with
another EGFR molecule or a different member of the
ErbB family (e.g., HER2). This is followed by phosphory-
lation of the tyrosine kinase residue, which in turn
induces the actual downstream signaling cascade [2-4].
Ligand-dependent activation of the EGFR tyrosine
kinase residues serve as binding sites of signal transdu-
cer and activator proteins that mediate the downstream
signaling processes of intracellular substrates [5]. The
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and Ras/MAPK pathway are major signaling mechan-
isms, and they function in the control of several impor-
tant biologic processes, including cell proliferation,
survival, angiogenesis, and migration as well as resis-
tance to apoptosis [6-8].
Due to the biologic significance of EGFR molecular
signaling in carcinomas, several monoclonal antibodies
against the ligand-binding domain of EGFR and small
molecule tyrosine kinase inhibitors of the tyrosine
kinase domain of EGFR have been investigated in the
therapy of malignant tumors (e.g., non-small cell lung
cancer [NSCLC], colorectal cancer [CRC] and metastatic
breast cancer [MBC]) [9-16]. It is important to study
whether EGFR is overexpressed in patients with breast
cancer since these patients can be given specific EGFR
molecule tyrosine kinase inhibitors such as gefitinib and
lapatinib [15,16]. There are only a few reports regarding
the overexpression of EGFR, with these studies indicat-
ing 8-36% of breast cancers over express this protein.
However, systematic studies appraising EGFR gene
amplification and mutations in the same set of cases
among Chinese female patients with breast cancer are
absent [17-19]. Many studies have concentrated on lung
cancers, where most patients ultimately have a relapse.
Mechanisms involved in resistance to targeted inhibition
of lung cancer include secondary resistance mutations,
inactivation of PTEN, activation of the MET pathway,
minor clones with KRAS mutations, and adenocarci-
noma transformation [20-32]. However, the mechanism
of drug resistance in breast cancer is unknown.
The purpose of the present study was to examine 139
formalin-fixed, paraffin-embedded specimens from Chi-
nese female patients with breast cancer, with a particu-
lar focus on the presence of EGFR gene amplification
and mutations. We attempted to explore the relation-
ship between EGFR copy numbers and EGFR mutations.
We also analyzed the correlation between EGFR gene
status and HER2 protein, estrogen receptor (ER), pro-
gesterone receptor (PR), and cytokeratin 5/6 (CK5/6)
expression as well as Ki-67 index proliferation and
intrinsic subtypes in these cases. In this study, we ana-
lyzed EGFR gene copy numbers by fluorescence in-situ
hybridization (FISH), and the mutations were analyzed
using a real-time (RT)-PCR detection kit.
Methods and Materials
Patient Information
One hundred and thirty-nine Chinese female patients
with breast cancer who underwent surgery at the
Department of Breast Oncology, Sun Yat-Sen University
Cancer Center, from Jan 2010 to May 2011 were
selected. The cases with primary breast cancer were ran-
domly selected from the archives of our Department of
Pathology based on the availability of blocks and suffi-
cient tissues. Additionally, only cases with available
EGFR FISH results, mutational status, and immunos-
taining were analyzed. Clinical information included age,
disease stage, tumor type, mass size, and axillary lymph
node metastasis status. The age interval of the patients
was 25-75 years, with a mean of 50.8 years. The TNM
Cancer Staging Manual 7th edition of the American
Joint Committee on Cancer (AJCC) [33] was used to
classify the cancer staging: stage 0, 2 cases; stage I, 28
cases; stage II, 78 cases; stage III, 30 cases; and stage IV,
1 case. Using immunohistochemistry as a surrogate defi-
nition of intrinsic subtypes for expression profiling,
cases that were ER and/or PR positive, HER2 negative,
and Ki-67 low (< 14%) were classified as luminal A can-
cers; cases that were ER and/or PR positive, HER2 nega-
tive, and Ki-67 high were classified as luminal B (HER2
positive) cancers; cases that were ER and/or PR positive,
any Ki-67, and HER2 overexpressed or amplified were
classified as luminal B (HER2 positive); cases that were
HER2 overexpressed or amplified and ER and PR absent
were classified as HER2 positive (non-luminal) cancers;
cases that were ER and PR absent, HER2 negative, and
CK5/6 and/or EGFR positive were classified as basal-like
cancers; and cases that lacked expression of ER, PR,
HER2, CK5/6, and EGFR were considered unclassified
[34-36]. The histopathological classification of breast
cancer in these cases was performed by an experienced
pathologist of our pathology department. Ethics
approval was obtained from the Ethical Review Commit-
tee of Sun Yat-Sen University Cancer Center, and
informed consent was obtained from all patients.
Tissue Preparation
Tissue microarrays were constructed using 0.6-mm tis-
sue cores as previously described [37]. One core from
the central and the other from the peripheral part of the
tumor were sampled for each tumor. For each case, 4-5
μm sections of formalin-fixed and paraffin-embedded
tissues were stained with Hematoxylin and Eosin for the
establishment of the histopathological tumor type and
differentiation grade.
Fluorescence In-Situ Hybridization Analysis of EGFR Gene
Copy Number
FISH analysis for EGFR gene copy number was per-
formed according to the manufacturer’sp r o t o c o lu s i n g
the GLP EGFR/CSP 7 probe (GP Medical Technologies,
Beijing, China). Simply, thet i s s u em i c r o a r r a ys e c t i o n s
were incubated at 65°C overnight. The slides were
deparaffinized in dimethyl benzene at room temperature
for 10 minutes and dehydrated in 100% ethanol. After
incubation in 30% sodium bisulfite at 50°C for 20-30
minutes, the sections were incubated in 2× saline
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minutes. The smears were digested with proteinase K
(0.20 mg/ml in 2× SSC; pH 7.0) for 20-30 minutes at
37°C, followed by a rinse in 2× SSC at room tempera-
ture for 5 minutes and then dehydration in 70%, 85%,
and 100% ethanol solutions in sequence. The solvents
were changed frequently and regularly so that all traces
of residual paraffin were removed in the above processes
[38]. After amplification of the GLP EGFR/CSP 7 probe
set, the slide was covered with a coverslip and sealed
with Indian rubber. The slides were heated at 80°C for
8-10 minutes and were then hybridized at 42°C over-
night. After a post-hybridization wash and dehydration
of the samples, 4’,6 ’-diamidino-2-phenylindole (DAPI)
was applied for chromatin counterstaining. At least 100
nuclei were scored for both EGFR gene signals and
chromosome 7 signals under a magnification of 1000×.
The ratio was defined as: the total number of red sig-
n a l s( E G F Rc o p yn u m b e r )d i v i d e db yt h en u m b e ro f
green signals (chromosome 7 copy number) in 100
nuclei. Tumors were scored as EGFR amplified when
the EGFR FISH-positive results were: a) ratio ≥2.0, b)
≥15 copies of the red signals per cell in ≥10% of total
cells, or c) the presence of EGFR gene clusters; or
scored as EGFR polysomy when: ratio < 2.0, but ≥40%
of cells display ≥4 copies. Meanwhile, EGFR FISH-nega-
tive include disomy (≥90% of cells display ≤2c o p i e s ) ,
low trisomy (≥40% of cells display ≤2c o p i e s ,1 0 - 4 0 %o f
cells display 3 copies, and < 10% of cells display ≥4
copies), high trisomy (≥40% of cells display ≤2c o p i e s ,
≥40% of cells display 3 copies, and < 10% of cells display
≥4 copies), and low polysomy (10-40% of cells display
≥4 copies) [38-40]. Healthy cells were used as controls.
Fluorescent PCR Method for Analysis of EGFR Gene
Mutations
The 5-μm formalin-fixed and paraffin-embedded tissues
were assayed for the presence of the most common
EGFR mutations in exon 19 (E746-A750 and L747-
P753insS short in-frame deletions) and exon 21 (L858R
and L861Q point mutations) using a RT-PCR detection
kit with the Taqman probe technique (GP Medical
Technologies, Beijing, China). Genomic DNA was
extracted from tissues using a TIANamp Genomic DNA
kit (Tiangen Biotech, Beijing, China). Two of the exon
19 deletions and the exon 21 mutations of the EGFR
gene were analyzed using fluorescently labeled RT-PCR
products.
Amplification reactions were setup using reagents
included in the Real Time PCR Detection Kit (GP Medi-
cal Technologies, Beijing, China), in accordance with the
manufacturer’s protocol. Essentially, the exon 19 PCR
reaction consisted of 5.4 ul deionized water, 7.5 ul 2 ×
PCR pre-mix, 0.15 ul forward primers-1, 0.15 ul reverse
primers-1, 0.15 ul probe-1 (delE746-A750), and 0.15 ul
probe-2 (delL747-P753insS) in a total volume of 13.5 ul.
The exon 21 PCR reaction consisted of 5.3 ul deionized
water, 7.5 ul 2 × PCR pre-mix, 0.15 ul forward primers-
2, 0.15 ul reverse primers-2, 0.2 ul probe-3 (L858R), and
0.2 ul probe-4 (L861Q) in a total volume of 13.5 ul. The
PCR cycling program was as follows: 50°C for 2 min,
95°C for 10 min, and 40 cycles of 95°C for 15 sec, 62°C
for 1 min. PCR analysis was performed by using an ABI
Prism 7500 Real-Time PCR equipment (Applied Biosys-
tems, Foster City, CA, USA) as previously described
[41,42].
Immunohistochemistry of EGFR Protein Expression
Immunohistochemical staining for EGFR was performed
on the 5-μm formalin-fixed, paraffin-embedded tissue
slide. EGFR was stained using the pharmDx kit accord-
ing to manufacturer’s instructions (DAKO). EGFR was
scored positive if any membranous tumor cell staining
was observed, whether or not it was completely circum-
ferential. Staining intensity was scored as follows: 0, no
membrane staining; 1+, weak staining intensity; 2+,
moderate staining intensity; 3+, strong staining intensity.
The staining intensity was multiplied by the percentage
of tumor cells be stained to obtain a total score, result-
ing in a possible range 0 to 300. Samples with an overall
score of 200 and higher were considered positive for
EGFR-overexpression.
Statistical analysis
SPSS version 13.0 software (SPSS, Chicago, IL, USA) was
used to analyze the data. Associations between EGFR
gene amplification and protein expression were evaluated
using Pearson’s chi-square test with cross tables. Differ-
ences of P < 0.05 were considered significant. Pearson’s
C h i - s q u a r e dt e s to rF i s h e r ’s exact test was also applied
for evaluation of multiple comparisons between EGFR
amplification and expression and age, disease stage,
tumor type, axillary lymph node metastasis status, and
immunohistochemical index (i.e., ER, PR, and HER2). A
P value < 0.05 was considered statistically significant.
Results
EGFR Gene Copy Numbers in Breast Carcinomas
We obtained both FISH and RT-PCR EGFR data on 139
female patients with breast cancer. A total of 48 (34.5%)
of the 139 tumors presented EGFR disomy, 6 tumors
(4.3%) presented low trisomy, 3 tumors (2.2%) presented
high trisomy, 36 (25.9%) tumors presented low polys-
omy, 42 tumors (30.2%) presented high polysomy, and 4
tumors (2.9%) presented amplification. From the total of
139 tumors, 46 (33.1%) presented positivity with FISH;
93 (66.9%) did not demonstrate EGFR gene amplifica-
tion (Figure 1).
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A total of 2 (1.4%) of the 139 tumors harbored EGFR
mutations, which include 1 exon 19 deletion with low
trisomy of the EGFR gene copy number and 1 exon 21
L858R mutation with high polysomy of the EGFR gene
copy number. None of the cases presented both of these
mutations. Overall, one tumor was poorly prognostic tri-
ple-negative moderate-grade invasive ductal carcinoma;
the other was also a moderate-grade invasive ductal car-
cinoma and ER positive. Both of the patients were post-
menopausal with pathological stage IIA and negative for
axillary lymph node metastasis.
EGFR Protein Expression in Breast Carcinomas
Based on immunohistochemistry, twenty-five (18.0%) of
the 139 cases had an immunohistochemical score of 200
or more; the remaining 114 (82.0%) cases showed a
negative result (Figure 2).
Association between the EGFR and Clinical and
Pathologic Features
The clinical and pathological features of all cases were
evaluated for the purpose of determining clinically relevant
correlations. EGFR gene copy number was associated with
Ki-67 proliferation index (P = 0.007). EGFR FISH positiv-
ity was not associated with clinical-pathological features,
including age (P = 0.265), lymph node metastasis (P =
0.765), disease stage (P = 0.748), tumor type (P = 0.551),
ER status (P = 0.464), PR status (P = 0.943), and HER2 sta-
tus (P = 0.733). The invasive ductal carcinomas group
showed a trend toward higher EGFR gene amplification,
although the association with tumor type was not statisti-
cally significant. EGFR protein expression was associated
with molecular subtypes (luminal subtypes vs. others, P =
0.010), grade (II vs. III, P = 0.001), ER (P = 0.002), and PR
(P < 0.001), respectively (Table 1).
Association of EGFR Protein Expression and EGFR Gene
Amplification
15 of the 46 breast carcinomas with EGFR FISH positiv-
ity showed immunohistochemical positive scores and 31
cases had negative results. There was a correlation
between protein overexpression and gene amplification,
the FISH-positive rate was significantly higher in the
IHC-positive group than in the IHC-negative group (P =
0.002) (Table 2).
Figure 1 Analysis of EGFR gene amplification and mutations based on FISH and RT-PCR analysis. A: FISH positive (amplification), B: FISH
negative (low trisomy), C: mutation positive (the left ascending curve represents the positive control, the right ascending curve represents the
exon 21 L858R mutation), D: mutation negative (the ascending curve represents the positive control). The virtual slide for this article can be
found here: http://www.diagnosticpathology.diagnomx.eu/vs/2521111805741248/1.
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The aim of this study was to evaluate the frequency of
EGFR gene amplification and mutations in 139 female
patients with breast cancer. It is known that EGFR gene
amplification indicates EGF-sensitive breast cancer. In
one study, EGFR gene amplification and/or high EGFR
expression were demonstrated as biological predictors of
poor prognosis in breast carcinoma [43]. Due to the
availability and benefit of anti-EGFR therapies, including
both monoclonal antibodies (MoAbs) and small mole-
cule tyrosine kinase inhibitors (TKI), for the treatment
of various solid malignant tumors, such as non-small
cell lung cancer (NSCLC), squamous cell carcinoma of
the head and neck (HNSCC), and colorectal cancer
(CRC), the role of EGFR gene status has been investi-
gated in a number of clinical studies. Several data sets
regarding EGFR gene amplification in breast cancer are
accessible. In various trials, EGFR gene amplification in
breast carcinomas was different, ranging between 0.8-28
percent. Khawla Al-Kuraya et al. [44] described EGFR
gene amplification in 0.8% of studied tumors, Jungsil Ro
et al. [43] reported positivity in 3 of the 21 evaluable
cases, Rohit Bhargava et al. [45] found positive EGFR
amplification in 11/175 (6%) of samples, Christian Ker-
sting et al. [46] showed EGFR whole gene amplification
in 4.7% of investigated cases, and in the cohorts of
Judith A. Gilbert et al. [47] and Jorge S Reis-Filho et al.
[48] 26% and 28% of the metastatic breast carcinomas
displayed high EGFR copy number, respectively. It is
likely that multiple techniques and scoring systems used
in the detection of EGFR amplification have led to the
inconsistent outcomes of these different trials.
In this current study we used FISH to detect EGFR
gene copy numbers in breast carcinomas. We identified
EGFR gene amplification in 46 (33.1%) of the 139
patients with breast cancer. This percentage is higher
than the range reported by the studies mentioned above.
It seems that the Chinese origin of the specimens, possi-
bly in addition to the use of various techniques and
scoring criteria, may possibly have contributed to the
Figure 2 EGFR protein expression by immunohistochemistry. A: Negative EGFR expression; B: 1+ EGFR expression; C: 2+ EGFR expression; D:
3+ EGFR expression. The virtual slide for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2521111805741248/2.
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characteristics
clinical-
pathological characteristic
Copy number Expression
Positive, N/% Negative, N/% P value Positive, N/% Negative, N/% P value
Age(years)
≤35 5/10.9 4/4.3 0.265
c 23/92.0 107/93.9 1.000
c
>35 41/89.1 89/95.7 2/8.0 7/6.1
Lymph node metastasis
Positive 23/50 49/52.7 0.765
a 16/64.0 56/49.1 0.178
a
Negative 23/50 44/47.3 9/36.0 58/50.9
Stage
0 0/0 2/2.2 0.748
a, $ 1/4.0 2/1.8 0.450
a, $
I 10/21.7 18/19.4 6/24.0 21/18.4
II 25/54.3 53/57 11/44.0 67/58.8
III 10/21.7 20/21.5 7/28.0 22/20.2
IV 1/2.2 0/0 0/0 1/0.9
Tumor type
DCIS 0/0 3/3.2 0.551
b, & 1/4.0 2/1.8 1.000
c, &
LCIS 0/0 0/0 0/0 0/0
IDC 44/95.7 83/89.2 23/92.0 104/91.2
ILC 0/0 3/3.2 0/0 3/2.6
Other 2/4.3 4/4.3 1/4.0 5/4.4
ER
Positive 33/71.7 72/77.4 0.464
a 13/52.0 92/80.7 0.002
a
Negative 13/28.3 21/22.6 12/48.0 22/19.3
PR
Positive 27/58.7 54/58.1 0.943
a 5/20.0 76/66.7 0.000
a
Negative 19/41.3 39/41.9 20/80.0 38/33.3
HER2
Positive 9/19.6 16/17.2 0.733
a 5/20.0 29/25.4 0.567
a
Negative 37/80.4 77/82.8 20/80.0 85/74.6
Ki-67 (%)
< 14 7/15.2 35/37.6 0.007
a 17/68.0 67/58.8 0.393
a
> 16 39/84.8 58/62.4 8/32.0 47/41.2
Subtypes
LUMA 9/19.6 28/30.1 0.628
a, ^ 4/16.0 33/28.9 0.010
c,^
LUMB (HER2-NEG) 17/37.0 32/34.4 7/28.0 42/36.8
LUMB (HER2-POS) 10/21.7 16/17.2 4/16.0 22/19.3
HER2 2/4.3 6/17.2 1/4.0 7/6.1
Basal-like 6/13.0 4/4.3 9/36.0 1/0.9
UC 2/4.3 7/7.5 0/0 9/7.9
Grade
I 0/0 0/0 0.921
a, # 0/0 0/0 0.001
a, #
II 31/67.4 52/55.9 10/40.0 73/64.0
III 12/26.1 21/22.6 13/52.0 20/17.5
UC 3/6.5 20/21.5 2/8.0 21/18.4
aP values (two-sided) calculated using Pearson’s chi-square test.
bP values (two-sided) calculated using Fisher’s exact test.
cP values (two-sided) calculated using Continuity Correction of Pearson’s chi-square test.
$Pearson’s chi-square test for stage 0-II and III- IV vs. EGFR status.
&Fisher’s exact test for invasive ductal carcinoma and other types vs. EGFR status.
^Pearson’s chi-square test for luminal subtypes and other subtypes vs. EGFR status.
#Grade II and III vs. EGFR status.
DCIS, ductal carcinoma in-situ; LCIS, lobular carcinoma in-situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR,
progesterone receptor; HER2, human epidermal growth factor receptor-2; Ki-67, Ki-67 proliferation index; LUMA, luminal A; LUMB (HER2-NEG), luminal B (HER2-
negative); LUMB (HER2-POS), luminal B (HER2-positive); UC, unclassified.
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showed EGFR gene amplification, which include 42
tumors (30.2%) presenting high polysomy and 4 tumors
(2.9%) presenting amplification (based on the ratio of
EGFR gene copies to CEP7 gene copies in at least 100
tumor cell nuclei). These data revealed that EGFR gene
amplification is a frequent event in Chinese patients
with breast carcinomas. As observed from this study,
EGFR positive immunostaining was consistent with
EGFR gene amplification. It appears that positive EGFR
protein overexpression could predict gene amplification
in breast cancers.
Activation of EGFR involves heterodimerization of
EGFR with HER2. Our results showed that there was no
correlation between EGFR and HER2 protein expression
(P = 0.567), which might indicated that activated EGFR
can form heterodimer not only with HER2, but also
with other members of ErbB family.
Currently, many trials have assayed for EGFR gene
amplification in order to identify patients that would
benefit from anti-EGFR therapy. Patients with EGFR
gene amplification have been connected to poor prog-
nosis in HNSCC [49,50] and NSCLC [51]. However,
patients with EGFR mutations have demonstrated an
increased benefit as compared to patients having EGFR
amplification [39]. EGFR gene mutations indicate sensi-
tivity to gefitinib, and it was demonstrated that about
85% of patients with NSCLC who obtained benefit from
gefitinib treatment were found to have mutations in
e x o n s1 8t o2 1o ft h et y r o s i n ek i n a s ed o m a i no ft h e
EGFR gene [51-54]. EGFR mutations in exon 19 (short
in-frame deletions) or 21 L858R (point mutation) affect
the adenosine triphosphate (ATP) pocket of the tyrosine
kinase domain leading to the activation of 4-anilinoqui-
nazoline compounds, which function to compete with
ATP [53]. Anti-EGFR therapy can consequently lead to
the downregulation of downstream signaling cascades,
such as the PI3K/Akt, RAS/Erk, MAPK, and STAT
pathways, responsible for cell proliferation and survival,
resulting in the inhibition of cell proliferation and
induction of cell apoptosis, respectively. The method for
EGFR-mutations used in this study can detect the most
common mutations of exons 19 and 21, but there are
still other mutations of exons 19 and 21 that cannot be
detected. Additionally, mutations of exons 18 and 20,
which can harbor upto 15% of EGFR-mutations in lung
cancer, cannot be analyzed in this way.
It is reported in some studies that EGFR gene muta-
tions in the tyrosine kinase domain in patients with
lung cancer are accompanied with a low increase in
EGFR gene copy number [55,56]. However, in this
study, EGFR gene mutations could be identified in only
2 out of 139 cases (1.4%) of the breast carcinoma sam-
ples, confirming that EGFR gene mutations are rare in
Chinese patients. Further trials with large samples and/
or different methods are highly recommended to be per-
formed to validate the observations mentioned above.
Conclusions
We observed that EGFR gene mutations were rare in
breast carcinomas, but EGFR gene amplification was
detected in about one third of the cases in this popula-
tion. In this study, rare mutations in the EGFR gene in
patients with breast cancer were detected, indicating
that EGFR gene mutations are infrequent in this cohort
of breast cancers. This suggested that EGFR mutation
analysis is not useful as a screening test for sensitivity to
anti-EGFR therapy for breast cancers. Nevertheless,
further studies will be required to investigate whether
EGFR gene copy number is a suitable screening test for
EGFR targeted therapy.
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